» Articles » PMID: 26858360

Differential Insulitic Profiles Determine the Extent of β-Cell Destruction and the Age at Onset of Type 1 Diabetes

Overview
Journal Diabetes
Specialty Endocrinology
Date 2016 Feb 10
PMID 26858360
Citations 166
Authors
Affiliations
Soon will be listed here.
Abstract

Type 1 diabetes (T1D) results from a T cell-mediated destruction of pancreatic β-cells following the infiltration of leukocytes (including CD8(+), CD4(+), and CD20(+) cells) into and around pancreatic islets (insulitis). Recently, we reported that two distinct patterns of insulitis occur in patients with recent-onset T1D from the U.K. and that these differ principally in the proportion of infiltrating CD20(+) B cells (designated CD20Hi and CD20Lo, respectively). We have now extended this analysis to include patients from the Network for Pancreatic Organ Donors with Diabetes (U.S.) and Diabetes Virus Detection (DiViD) study (Norway) cohorts and confirm that the two profiles of insulitis occur more widely. Moreover, we show that patients can be directly stratified according to their insulitic profile and that those receiving a diagnosis before the age of 7 years always display the CD20Hi profile. By contrast, individuals who received a diagnosis beyond the age of 13 years are uniformly defined as CD20Lo. This implies that the two forms of insulitis are differentially aggressive and that patients with a CD20Hi profile lose their β-cells at a more rapid rate. In support of this, we also find that the proportion of residual insulin-containing islets (ICIs) increases in parallel with age at the onset of T1D. Importantly, those receiving a diagnosis in, or beyond, their teenage years retain ∼40% ICIs at diagnosis, implying that a functional deficit rather than an absolute β-cell loss may be causal for disease onset in these patients. We conclude that appropriate patient stratification will be critical for correct interpretation of the outcomes of intervention therapies targeted to islet-infiltrating immune cells in T1D.

Citing Articles

Beyond the loss of beta cells: a quantitative analysis of islet architecture in adults with and without type 1 diabetes.

Verschueren van Rees N, Ashwin P, McMullan C, Krogvold L, Dahl-Jorgensen K, Morgan N Diabetologia. 2025; .

PMID: 40011232 DOI: 10.1007/s00125-025-06376-9.


Emerging Immunotherapies for Disease Modification of Type 1 Diabetes.

Foster T, Bruggeman B, Haller M Drugs. 2025; .

PMID: 39873914 DOI: 10.1007/s40265-025-02150-8.


Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes.

Redondo M, Cuthbertson D, Steck A, Herold K, Oram R, Atkinson M Diabetologia. 2024; 68(3):588-601.

PMID: 39670998 PMC: 11832693. DOI: 10.1007/s00125-024-06338-7.


New horizon of the combined BCG vaccine with probiotic and liraglutide in augmenting beta cell survival suppression of TXNIP/NLRP3 pyroptosis signaling in Streptozocin-Induced diabetes mellitestype-1 in rats.

Khalifa A, Abdelrahim D, Mekawy D, Hamed R, Mohamed W, Ramadan N Heliyon. 2024; 10(20):e38932.

PMID: 39640632 PMC: 11620097. DOI: 10.1016/j.heliyon.2024.e38932.


Age and sex mark clinical differences in the presentation of pediatric type 1 diabetes mellitus.

Gupta E, Huang X, Velasquez H, Golani K, Siller A, Minard C J Pediatr Endocrinol Metab. 2024; 38(1):22-28.

PMID: 39602489 DOI: 10.1515/jpem-2024-0451.